Exchange: NASDAQ·Updated 04:23 PM EDT
News
all
press releases
The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP
Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.
Zacks
More News
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
Zacks
Healthcare ETFs Are Looking Up: Here's Why
Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.
Zacks
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment
U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.
Stocktwits
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks
The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM
IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.
Zacks
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Zacks
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks

Advertisement|Remove ads.